*To the Editor*:

We read the *post hoc* analysis of the SMART (Isotonic Solutions and Major Adverse Renal Events Trial) trial with great interest, agree with the authors' assertions that balanced crystalloids are likely to be the most appropriate choice for critically ill patients experiencing sepsis, and respect the concerns about unequivocally recommending their judicious use ([@bib1]). Although the critical care community awaits results from the PLUS (Plasma-Lyte 148 versus Saline) and BaSICS (Balanced Solution versus Saline in Intensive Care Study) studies, many institutions and providers are considering or already have implemented pathways and protocols for sepsis management that provide guidance for the choice of crystalloids during resuscitation. These management strategies may be more completely informed if all of the high-quality data for fluid resuscitation with balanced crystalloids versus saline in sepsis, including the recently published *post hoc* analysis of SMART, were considered.

A recently published systematic review and meta-analysis attempted to clarify the impact of using balanced crystalloids in sepsis; however, including these new data with previously published controlled trials and observational studies improves on those efforts ([@bib2]). When prior data are considered alongside the SMART *post hoc* analysis, the benefit on short-term mortality appears less certain, although potentially still impactful (odds ratio \[OR\], 0.88; 95% confidence interval \[CI\], 0.76--1.01) ([@bib1], [@bib3]--[@bib5]) ([Figure 1](#fig1){ref-type="fig"}). We have greater confidence in the decreased odds of patients developing acute kidney injury (OR, 0.67; 95% CI, 0.49--0.92) but uncertainty regarding progression to receipt of renal replacement therapy (OR, 0.85; 95% CI, 0.71--1.03) when receiving balanced crystalloids ([@bib1], [@bib4]--[@bib6]). Although two of the three individual outcomes did not show significance, there was a lower incidence of major adverse kidney events in 30 days with balanced crystalloids compared with saline (OR, 0.78; 95% CI, 0.65--0.94) in the two studies that evaluated this outcome ([@bib1], [@bib6]). Differences in this composite outcome, which are not being driven by a particular intermediate clinical endpoint, are extremely encouraging for balanced crystalloid use.
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When financial costs are considered, the proposition of using a balanced crystalloid rather than saline becomes even more attractive. Although Plasma-Lyte 148 is almost three times more costly than saline, lactated Ringer's is available at approximately the same purchase price as saline. The majority of patients in most published studies who were prescribed a balanced crystalloid received lactated Ringer's ([@bib1], [@bib4]--[@bib6]). Given the significant costs associated with poor clinical outcomes and adverse events during critical illness, using lactated Ringer's in critically ill patients with sepsis is likely to be a substantially cost-effective intervention in most scenarios.

We hope that the fine work by Brown and colleagues will be considered favorably alongside other published evaluations of balanced crystalloids versus saline in critically ill adults ([@bib1]). At this time, we believe providing fluid resuscitation with balanced crystalloids, particularly lactated Ringer's, to adult patients with sepsis is likely a more effective and cost-effective intervention than saline.
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